Quick Answer
SANGAMO THERAPEUTICS, INC reported Research And Development Expense of $112.67 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +1.0% in Research And Development Expense from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Research And Development Expense has grown by 288.7%.
- Historical annual values: Fiscal year 2025: $112.67 million | Fiscal year 2024: $111.52 million | Fiscal year 2023: $234.06 million | Fiscal year 2022: $249.90 million | Fiscal year 2021: $230.82 million | Fiscal year 2020: $180.65 million | Fiscal year 2019: $145.92 million | Fiscal year 2018: $114.87 million | Fiscal year 2017: $65.73 million | Fiscal year 2016: $65.62 million | Fiscal year 2015: $67.20 million | Fiscal year 2014: $56.97 million | Fiscal year 2013: $37.04 million | Fiscal year 2012: $31.71 million | Fiscal year 2011: $32.10 million | Fiscal year 2010: $33.15 million | Fiscal year 2009: $28.98 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: